Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
Form 144 summary for BridgeBio Pharma, Inc. (BBIO)
This Form 144 reports an insider sale on 08/05/2025: 17,167 common shares sold through Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) with an aggregate market value of $841,183.00. The filing lists 189,880,720 shares outstanding. The securities were acquired and paid for on 08/05/2025 via a stock option exercise from the issuer with cash payment. The filer reports "Nothing to Report" for securities sold in the past three months.
Note: Several filer and issuer contact fields in the form are blank in the provided text.